Day: November 15, 2021

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) — BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a leading healthcare products and services provider, today announced its unaudited financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights:Revenues. Revenues for the three months ended September 30, 2021 increased to $13,777,494 from $3,091,071 in the comparable period in 2020, an increase of $10,686,423, or 345.7%.Gross profit. Gross profit for the three months ended September 30, 2021 increased to $2,029,109 from $257,278 in the comparable period in 2020, an increase of $1,771,831, or 688.7%.“We are glad to achieve significant revenue growth in the third quarter. The growth was mainly driven by the increase in sales of wholesale pharmaceuticals. Contributing to the...

CHRISTIANSTED, U.S. Virgin Islands, Nov. 15, 2021 (GLOBE NEWSWIRE) — Altisource Asset Management Corporation (“AAMC” or the “Company”) (NYSE American: AAMC) today announced financial and operating results for the second quarter of 2021. Third Quarter 2021 Highlights and Recent DevelopmentsMaintained liquidity to position the Company to have access to capital to consummate prospective business opportunities. Liquidity consists of $84.5 million in cash. Negotiated a settlement agreement on 18,200 shares of our Series A Convertible Preferred Stock (“Series A Shares”) with certain investors which resulted in a $16.1 million increase to equity on the balance sheet, and reduced the overall Series A Shares balance to $150 million. All remaining equity securities were divested during the quarter. The Company is no longer an “investment...

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and webcast to be held tomorrow at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2021, and provided operational updates. “We continued to make progress during third quarter 2021 towards our objectives of growing XHANCE and successfully completing our chronic sinusitis program,” stated CEO Peter Miller. “XHANCE net revenue increased 41% compared to third quarter 2020 and we completed enrollment in the second of our two...

Third quarter 2021 revenue of $32.2 million and net income of $11.2 million Strong growth in user transaction profitability AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) — Lottery.com Inc. (Nasdaq: LTRY, LTRYW) (“Lottery.com” or the “Company”), a leading technology company that is transforming how, where and when lottery is played, reported financial results for the third quarter ended September 30, 2021. These results were achieved prior to the closing of the Company’s business combination with Trident Acquisitions Corp. on October 29, 2021. The Company’s unaudited financial statements for the third quarter of 2021 and other information have been filed in a Current Report on Form 8-K/A today with the U.S. Securities and Exchange Commission (“SEC”). Tony DiMatteo, Lottery.com Co-Founder and CEO, commented, “We are proud of the...

FORT WORTH, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) — Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) announced today its financial results for the third quarter ended September 30, 2021.   Third Quarter 2021 Highlights and Recent DevelopmentsProduction sales of 2,426 MBoe for the third quarter of 2021, or 26.4 MBoe per day, compared to 1,587 MBoe, or 17.2 MBoe per day in the prior year quarter.Net loss was $15.2 million for the current year quarter, compared to a net loss of $6.8 million in the prior year quarter. Adjusting both quarters to exclude pre-tax, non-cash mark-to-market losses related to our commodity price derivatives of $35.5 million and $13.0 million, respectively, net income before income taxes would have been approximately $19.2 million and $6.9 million for the current and prior...

PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) — Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for the third quarter 2021 compared to revenues of $410 thousand, an operating loss of $565 thousand and a net loss of $678 thousand or $0.02 per diluted share for the same period in 2020. For the nine months ended September 30, 2021, the Company reported revenues of $1.5 million, an operating loss of $977 thousand and a net loss of $908 thousand...

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the third quarter ended September 30, 2021. As of September 30, 2021, the Fund’s net assets were approximately $98.8 million, or $14.33 per share, compared with net assets of approximately $107.3 million, or $15.57 per share as of June 30, 2021. As of September 30, 2021, the Fund’s portfolio included public and private securities valued at approximately $96.5 million, or $14.00 per share, which includes approximately $0.03 per share in cash and cash equivalents. Portfolio Summary (as of 9/30/21)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $96.27 million $13.97Cash/Cash...

Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End  BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter ended September 30, 2021. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “In the third quarter Timber was excited to complete the Phase 2b CONTROL Study of congenital ichthyosis for its lead asset, TMB-001. The positive topline data was released in early October and demonstrated clinically...